These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23711991)

  • 41. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease.
    Großekatthöfer M; Güclü ED; Lawitschka A; Matthes-Martin S; Mann G; Minkov M; Peters C; Seidel MG
    Ann Hematol; 2013 Aug; 92(8):1121-8. PubMed ID: 23604429
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease.
    Petersen SL; Madsen HO; Ryder LP; Svejgaard A; Masmas TN; Dickmeiss E; Heilmann C; Vindeløv LL
    Biol Blood Marrow Transplant; 2004 May; 10(5):337-46. PubMed ID: 15111933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytotoxic T lymphocyte precursor frequency as a predictor of acute graft-versus-host disease in bone marrow transplantation from HLA-identical siblings.
    Affaticati P; Locatelli F; Roggero S; Marmont F; Falda M; Dall'Omo AM; Busca A; Ceretto C; Praticò L; Berrino M; Curtoni ES
    Bone Marrow Transplant; 2000 Sep; 26(5):517-23. PubMed ID: 11019841
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Huang XJ; Jiang Q; Chen H; Xu L; Liu D; Chen Y; Han W; Zhang Y; Liu K; Lu D
    Bone Marrow Transplant; 2005 Aug; 36(4):343-8. PubMed ID: 15968295
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies.
    Chang YJ; Zhao XY; Huang XJ
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):323-34. PubMed ID: 18275899
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Allogeneic peripheral blood stem cell transplantation in the treatment of hematologic malignancies].
    Wang F; Huang X; Ren H; Zhang Y; Xu L; Chen Y; Liu K; Guo N; Lu D
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):403-6. PubMed ID: 12411042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
    Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
    [TBL] [Abstract][Full Text] [Related]  

  • 49. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.
    Remberger M; Naseh N; Aschan J; Barkholt L; LeBlanc K; Svennberg P; Ringdén O
    Bone Marrow Transplant; 2003 Jul; 32(2):217-23. PubMed ID: 12838288
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
    Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
    Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
    Malard F; Szydlo RM; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Mohty M
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):28-34. PubMed ID: 20053329
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated soluble human leukocyte antigen G levels in patients after allogeneic stem cell transplantation are associated with less severe acute and chronic graft-versus-host disease.
    Kordelas L; da Silva Nardi F; Wagner B; Ditschkowski M; Liebregts T; Lindemann M; Heinemann FM; Horn PA; Beelen DW; Rebmann V
    Bone Marrow Transplant; 2018 Sep; 53(9):1149-1156. PubMed ID: 29540850
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Soluble total human leukocyte antigen class I and human leukocyte antigen-G molecules in kidney and kidney/pancreas transplantation.
    Rebmann V; Bartsch D; Wunsch A; Möllenbeck P; Golda T; Viebahn R; Grosse-Wilde H
    Hum Immunol; 2009 Dec; 70(12):995-9. PubMed ID: 19651178
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation.
    Pastore D; Delia M; Mestice A; Carluccio P; Perrone T; Gaudio F; Curci P; Rossi AR; Ricco A; Specchia G
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):887-93. PubMed ID: 22062803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of CD3+CD4-CD8- (double negative) T cells reconstitution in patients following hematopoietic stem-cell transplantation.
    Ye H; Chang Y; Zhao X; Huang X
    Transpl Immunol; 2011 Dec; 25(4):180-6. PubMed ID: 21911061
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
    Huang X; Liu D
    Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
    Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
    Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.